Pfizer’s Mylotarg looks set for a return to the US market after FDA advisers recommended its use in acute myeloid leukaemia. The drug comes with a fascinating history, and in many ways was a ...

Vor Biopharma's trem-cel offers hope for AML treatment, but financial risks and early-stage progress suggest caution. Learn ...

Pfizer’s Mylotarg is back on the US market after a seven-year absence, after the FDA reapproved it in the aggressive blood cancer, acute myeloid leukaemia. The world’s first approved antibody ...

Clinical trial complexity, logistical challenges associated with treatments, and resource constraints at trial sites cited as top factors that delay enrollment into cell and gene therapy (CGT ...

Detailed price information for Vor Biopharma Inc (VOR-Q) from The Globe and Mail including charting and trades.

Antibodies and related products are the fastest growing class of therapeutic agents. By analysing the regulatory approvals of IgG-based biotherapeutic agents in the past 10 years, we can gain ...

2024年，百利天恒可谓风光无限，其股价涨幅超38%，营收涨幅更是超900%；62岁的掌舵人朱义身价随之增长超500亿元，成为2024年科创板首富。 1963年，朱义生于四川南充，本科毕业于四川大学无线电系，硕士毕业于复旦大学生物系，博士回到四川大学读企业金融。毕业后，朱义当过教师，做过医药代理，也搞过房地产，赚了第一桶金。

the potential of trem-cel to enable targeted therapies in the post-transplant setting including Mylotarg and CD33-targeted CAR-Ts while maintaining healthy blood count levels and change the ...

In the second half of the same year, Vor plans to share updated data from the Phase 1/2a VBP101 trial of trem-cel in combination with Mylotarg. These are the recent developments at Vor Biopharma.